[P-glycoprotein activity in vivo in older adults: physiological, -pathophysiological and pharmacokinetic interplay at the blood-brain barrier].

Activité de la p-glycoprotéine in vivo chez la personne âgée : intrications physiologique, physiopathologique et pharmacocinétique au niveau de la barrière hémato-encéphalique.

Journal

Geriatrie et psychologie neuropsychiatrie du vieillissement
ISSN: 2115-7863
Titre abrégé: Geriatr Psychol Neuropsychiatr Vieil
Pays: France
ID NLM: 101553404

Informations de publication

Date de publication:
01 Jun 2024
Historique:
medline: 18 7 2024
pubmed: 18 7 2024
entrez: 18 7 2024
Statut: ppublish

Résumé

p-glycoprotein (P-gp) is an efflux transporter of xenobiotic and endogenous compounds across the blood-brain barrier (BBB). P-gp plays an essential role by limiting passage of these compounds into the brain tissue. It is susceptible to drug-drug interactions when interactors drugs are co-administrated. The efficiency of P-gp may be affected by the aging process and the development of neurodegenerative diseases. Studying this protein in older adults is therefore highly relevant for all these reasons. Understanding P-gp activity in vivo is essential when considering the physiological, pathophysiological, and pharmacokinetic perspectives, as these aspects seem to be interconnected to some extent. In vivo exploration in humans is based on neuroimaging techniques, which have been improving over the last years. The advancement of exploration and diagnostic tools is opening up new prospects for understanding P-gp activity at the BBB.

Identifiants

pubmed: 39023148
pii: pnv.2023.1170
doi: 10.1684/pnv.2023.1170
doi:

Substances chimiques

ATP Binding Cassette Transporter, Subfamily B, Member 1 0

Types de publication

Journal Article Review English Abstract

Langues

fre

Sous-ensembles de citation

IM

Pagination

137-144

Auteurs

Théodore Decaix (T)

Université Paris Cité, CNRS, CiTCoM, Paris, France, Département de gériatrie, Hôpital Lariboisière - Fernand-Widal, Assistance publique-Hôpitaux de Paris, Paris, France.

Agathe Vrillon (A)

Université Paris Cité, Inserm, UMRS 1144, Paris, France, Centre de neurologie cognitive, Hôpital Lariboisière - Fernand-Widal, Assistance publique-Hôpitaux de Paris, Paris, France.

Claire Paquet (C)

Université Paris Cité, Inserm, UMRS 1144, Paris, France, Centre de neurologie cognitive, Hôpital Lariboisière - Fernand-Widal, Assistance publique-Hôpitaux de Paris, Paris, France.

Olivier Laprévote (O)

Université Paris Cité, CNRS, CiTCoM, Paris, France, Département de biochimie, Centre hospitalier national d'ophtalmologie des Quinze-Vingts, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH